Dana-Farber Cancer Institute researchers unveiled a platform to systematically discover molecular glues that redirect E3 ligases toward previously “undruggable” proteins. The approach targets the challenge that degraders currently use only a small subset of E3 ligases. The work, published in Nature, also reported the first metabolically activated molecular glue degrader—suggesting that glue activity can be tuned by cellular context rather than being purely static. The platform was framed as scalable discovery infrastructure intended to expand the molecular glue toolkit for cancers and beyond, building on prior molecular glue precedents such as lenalidomide’s E3-ligase redirection mechanism.